Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118899 | 0.80 | — | — | |
| SCHEMBL6739890 | 0.80 | — | — | |
| Water SCHEMBL29412656 | 0.76 | — | — | |
| SCHEMBL3028842 | 0.76 | — | — | |
| Methylene Chloride SCHEMBL1604482 | 0.75 | HTT (0.30) | — | |
| Dimethylformamide SCHEMBL4046504 | 0.72 | TSHR (0.53) | — | |
| Benzene SCHEMBL5152353 | 0.71 | HTT (0.38) | — | |
| SCHEMBL8091799 | 0.70 | CA2 (0.34) | — | |
| Diethylamine SCHEMBL1654811 | 0.69 | — | — | |
| SCHEMBL1584491 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-07-02 | — | — | US | disclosed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2019-05-02 | — | — | US | disclosed |
| EP-3316863-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-01-04 | — | — | US | disclosed |
| WO-2017210246-A2 | PENICILLAMINE CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9750818-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3160518-A2 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-04-06 | — | — | US | disclosed |
| WO-2017003940-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016004048-A2 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | BLEND THERAPEUTICS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR4, SSTR5, SSTR1 | TP53 2681/4885 |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | TP53 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.